骨髓瘤细胞全基因组CRISPR-Cas9筛选鉴定免疫调节药物敏感性调控因子
该研究利用全基因组CRISPR-Cas9筛选探索多发性骨髓瘤细胞对免疫调节药物(IMiDs)敏感性的机制。研究发现CSN9信号体复合物通过抑制SCFFbxo7 E3连接酶介导的CRBN降解而赋予IMiDs敏感性,反之则增强CRBN降解导致耐药。蛋白酶体抑制剂或NEDD8激活酶(NAE)抑制剂预处理可维持CRBN水平并增强IMiDs敏感性。
要点
- CSN9信号体复合物抑制SCFFbxo7介导的CRBN降解,从而赋予IMiDs敏感性。
- CSN9功能缺失激活SCFFbxo7,增强CRBN降解并导致IMiDs耐药。
- 蛋白酶体抑制剂或NAE抑制剂预处理可维持CRBN水平,增强IMiDs敏感性。
核心结论
- CSN9信号体复合物通过调控CRBN表达来调节多发性骨髓瘤细胞对IMiDs的敏感性。
研究设计与样本
- 研究采用全基因组CRISPR-Cas9筛选技术,研究对象为多发性骨髓瘤细胞。
主要发现
- CSN9信号体复合物作为Cullin-RING泛素连接酶的去激活剂,抑制SCFFbxo7 E3连接酶介导的CRBN降解,从而赋予IMiDs敏感性。
- CSN9信号体功能缺失激活SCFFbxo7复合物,增强CRBN降解,导致IMiDs耐药。
- 蛋白酶体抑制剂或NEDD8激活酶(NAE)抑制剂预处理可阻止CRBN降解并维持其水平,从而增强IMiDs敏感性。
关键数值与推荐
- 未报告关键数值与推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunomodulatory drugs (IMiDs) including lenalidomide and pomalidomide bind cereblon (CRBN) and activate the CRL4CRBN ubiquitin ligase to trigger proteasomal degradation of the essential transcription factors IKZF1 and IKZF3 and multiple myeloma (MM) cytotoxicity. We have shown that CRBN is also targeted for degradation by SCFFbxo7 ubiquitin ligase. In the current study, we explored the mechanisms underlying sensitivity of MM cells to IMiDs using genome-wide CRISPR-Cas9 screening. We validate that CSN9 signalosome complex, a deactivator of Cullin-RING ubiquitin ligase, inhibits SCFFbxo7 E3 ligase-mediated CRBN degradation, thereby conferring sensitivity to IMiDs; conversely, loss of function of CSN9 signalosome activates SCFFbxo7 complex, thereby enhancing degradation of CRBN and conferring IMiD resistance. Finally, we show that pretreatment with either proteasome inhibitors or NEDD8 activating enzyme (NAE) inhibitors can abrogate degradation and maintain levels of CRBN, thereby enhancing sensitivity to IMiDs. These studies therefore demonstrate that CSN9 signalosome complex regulates sensitivity to IMiDs by modulating CRBN expression.
引用
- Liu J, Song T, Zhou W, et al. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2018. PMID: 30026574. doi:10.1038/s41375-018-0205-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。